{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"62"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"72"}],"units":"Participants"}],"description":"An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 24 weeks post last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and all non-serious AEs. Participants were followed up to 24 weeks after study drug last dose.","groups":[{"description":"Participants received placebo matched to tanezumab SC once every 8 weeks for 24 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants in this discontinued treatment arm, received tanezumab 10 mg SC once every 8 weeks before protocol amendment 3 and completed their treatment before the amendment.","id":"OG001","title":"Tanezumab 10 mg"},{"description":"Participants in this treatment group had received tanezumab 10 mg SC once every 8 weeks before protocol amendment 3 and after the amendment they continued remaining treatment with tanezumab 20 mg SC once every 8 weeks.","id":"OG002","title":"Tanezumab 10/20 mg"},{"description":"Participants received tanezumab 20 mg SC once every 8 weeks for 24 weeks.","id":"OG003","title":"Tanezumab 20 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety analysis set was defined as all participants treated with tanezumab or placebo SC, including participants who received tanezumab 10 mg prior to protocol amendment 3.","reportingStatus":"POSTED","timeFrame":"Day 1 of dosing up to 24 weeks post last dose (maximum up to Week 48)","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}